Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 11/20 | 0.56 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | ACLY | P53396 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | DPP4 | P27487 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4709304 | 0.86 | MAPK8 (0.70) | MAPK8DPP4 | |
| SCHEMBL22022202 | 0.84 | PLA2G2A (0.52) | MAPK8PLA2G2AALDH1A1ACLYMAPT | |
| SCHEMBL11729659 | 0.79 | KMT2A (0.56) | MAPK8ALDH1A1ACLYMAPTDPP4 | |
| SCHEMBL11730958 | 0.78 | ALDH1A1 (0.51) | MAPK8ALDH1A1ACLYKMT2A | |
| SCHEMBL22003802 | 0.78 | HTR6 (0.56) | ALDH1A1ACLYMAPTDPP4 | |
| SCHEMBL22003908 | 0.77 | ACLY (0.78) | MAPK8PLA2G2AACLYMAPT | |
| SCHEMBL6090931 | 0.76 | KMT2A (0.58) | MAPK8PLA2G2AALDH1A1MAPTKMT2A | |
| SCHEMBL4713124 | 0.76 | MAPK8 (0.81) | MAPK8 | |
| SCHEMBL12044037 | 0.76 | EDNRB (0.55) | MAPK8PLA2G2AALDH1A1MAPTKMT2A | |
| SCHEMBL4711159 | 0.75 | MAPK8 (0.60) | MAPK8DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200157076-A1 | ACLY INHIBITORS AND USES THEREOF | NIMBUS DISCOVERY, INC. | 2020-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200157076-A1 | ACLY INHIBITORS AND USES THEREOF | ACLY, ATP5ME, ATP5MG | MAPK8 3384/4885PLA2G2A 3356/4885ALDH1A1 1455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.